Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment

Autor: Piet Geusens, Melissa SAM Bevers, Bert van Rietbergen, Osvaldo D Messina, Eric Lespessailles, Beatriz Oliveri, Roland Chapurlat, Klaus Engelke, Arkadi Chines, Shuang Huang, Kenneth G Saag, Joop P van den Bergh

Publikováno v: Journal of Bone and Mineral Research, 37(6), 1136-1146. Wiley-Blackwell
Journal of Bone and Mineral Research, 37(6), 1136-1146. Wiley

In a randomized clinical trial in patients initiating glucocorticoid therapy (GC-I) or on long-term therapy (GC-C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than daily risedronate. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd76969da7ab652d9ebc89d373a52839
https://pubmed.ncbi.nlm.nih.gov/35340062